BSE
506919

Makers Laboratories Limited

Drug Manufacturers - Major
Healthcare

Prices are adjusted according to historical splits.

Makers Laboratories Limited Stock Price

Vitals

Today's Low:
₹103.3
Today's High:
₹106.35
Open Price:
₹106
52W Low:
₹94
52W High:
₹166
Prev. Close:
₹104.25
Volume:
1517

Company Statistics

Market Cap.:
₹504.97 million
Book Value:
105.624
Revenue TTM:
₹467.77 million
Operating Margin TTM:
4.81%
Gross Profit TTM:
₹214.77 million
Profit Margin:
2.43%
Return on Assets TTM:
1.82%
Return on Equity TTM:
2.48%

Company Profile

Makers Laboratories Limited had its IPO on under the ticker symbol 506919.

The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Makers Laboratories Limited has a staff strength of 135 employees.

Stock update

Shares of Makers Laboratories Limited opened at ₹106 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹103.3 - ₹106.35, and closed at ₹104.35.

This is a +0.1% increase from the previous day's closing price.

A total volume of 1,517 shares were traded at the close of the day’s session.

In the last one week, shares of Makers Laboratories Limited have slipped by -3.38%.

Makers Laboratories Limited's Key Ratios

Makers Laboratories Limited has a market cap of ₹504.97 million, indicating a price to book ratio of 1.1638 and a price to sales ratio of 1.2884.

In the last 12-months Makers Laboratories Limited’s revenue was ₹467.77 million with a gross profit of ₹214.77 million and an EBITDA of ₹51.15 million. The EBITDA ratio measures Makers Laboratories Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Makers Laboratories Limited’s operating margin was 4.81% while its return on assets stood at 1.82% with a return of equity of 2.48%.

In Q3, Makers Laboratories Limited’s quarterly earnings growth was a positive 200% while revenue growth was a negative 20.7%.

Makers Laboratories Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
53.0736
PEG

Its diluted EPS in the last 12-months stands at ₹2.319 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Makers Laboratories Limited’s profitability.

Makers Laboratories Limited stock is trading at a EV to sales ratio of 1.4777 and a EV to EBITDA ratio of 13.273. Its price to sales ratio in the trailing 12-months stood at 1.2884.

Makers Laboratories Limited stock pays annual dividends of ₹1 per share, indicating a yield of 1.31% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
₹1.52 billion
Total Liabilities
₹275.38 million
Operating Cash Flow
₹12.53 million
Capital Expenditure
₹129.07 million
Dividend Payout Ratio
0%

Makers Laboratories Limited ended 2024 with ₹1.52 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.52 billion while shareholder equity stood at ₹692.01 million.

Makers Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹275.38 million in other current liabilities, 59004000.00 in common stock, ₹633.01 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹49.79 million. The company’s total short-term debt was ₹45,542,000 while long-term debt stood at ₹43.18 million.

Makers Laboratories Limited’s total current assets stands at ₹633.37 million while long-term investments were ₹0 and short-term investments were ₹6.10 million. Its net receivables were ₹198.67 million compared to accounts payable of ₹0 and inventory worth ₹313.21 million.

In 2024, Makers Laboratories Limited's operating cash flow was ₹12.53 million while its capital expenditure stood at ₹129.07 million.

Comparatively, Makers Laboratories Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price
₹104.35
52-Week High
₹166
52-Week Low
₹94
Analyst Target Price

Makers Laboratories Limited stock is currently trading at ₹104.35 per share. It touched a 52-week high of ₹166 and a 52-week low of ₹166. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹112.74 and 200-day moving average was ₹112.05 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6644.2% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Makers Laboratories Limited

The stock symbol (also called stock or share ticker) of Makers Laboratories Limited is 506919

The IPO of Makers Laboratories Limited took place on

Similar Industry Stocks (Drug Manufacturers - Major)

Last Price
Chg
Chg%
₹0.25
0
+0.56%
₹23.01
-0.87
-3.64%
₹4.42
-0.01
-0.23%
Eneti Inc (NETI)
₹10.42
0.18
+1.76%
₹0.03
0
+7.73%
₹0.17
0
+0.06%
₹0.09
0
0%
₹0
-0
-13.33%
Arko Corp (ARKOW)
₹1.17
0
0%
₹19.54
0.07
+0.36%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers products in general health therapeutic segments, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeal, anti-emetics and anti-nauseants, anti-fungal, anti?inflammatory, analgesic, anti-spasmodic, anti-malarial, anti-thyroid, cough and cold control, digestives, neurotonic, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties. It also provides diabetic and hypertensive drugs. The company’s principal formulation brands comprise Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin. It serves approximately 1,500 stockiests’; 1,00,000 doctors; and 2,00,000 retailers through a distribution network of 20 consignment agents and 15 super stockiests’. The company was incorporated in 1984 and is based in Mumbai, India.

Address

54-D, Kandivli Industrial Estate, Mumbai, India, 400067